The KEYNOTE-158 phase 2 trial aimed to investigate the efficacy and safety of pembro in Chinese descent patients with MSI-H/dMMR tumors. The primary endpoint was to determine ORR. Researchers noticed that pembro demonstrated clinically meaningful antitumor activity and durable responses in Chinese patients with MSI-H/dMMR tumors. The multicohort KEYNOTE-158 trial played a pivotal […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background Chimeric antigen receptor (CAR)-T cells face many obstacles in solid tumor therapy, including heterogeneous antigen expression and inefficient T cell persistence. Guanylyl cyclase C (GUCY2C) has been identified as a suitable tumor antigen for targeted …
Background In addition to their established action of synthetic lethality in tumor cells, poly(ADP-ribose) polymerase inhibitors (PARPis) also orchestrate tumor immune microenvironment (TIME) that contributes to suppressing tumor growth. However, it remains not fully understood whether …
Background HBM4003 is a novel anti-CTLA-4 heavy chain-only antibody, designed to enhance Treg ablation and antibody-dependent cell-mediated cytotoxicity while ensuring a manageable safety profile. This phase I trial investigated the safety, pharmacokinetics, immunogenicity and preliminary efficacy …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
